Evaluation of new putative tumor markers for melanoma
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Background: The early diagnosis of recurrent melanoma can contribute to better outcome if the disease can be surgically resected or if the metastases are responsive to systemic therapies. Lipid-associated sialic acid (LASA-P) and the S-100 protein (S-100) were evaluated as tumor markers for melanoma with the goal of early detection of recurrence.
Methods: Sixty-seven patients were identified who had levels of S-100 and LASA-P drawn during their clinical course. A multivariate regression analysis was performed to determine the significance of the serum markers in relation to other prognostic factors for melanoma.
Results: After a median follow-up of 30 months, 58 patients had recurrences, and 49 patients died of disease. LASA-P elevation was not associated with the time to recurrence (p=0.2176) or survival (p=0.2507). S-100 positivity was a significant predictor of recurrence (p<0.0001) and survival (p=0.0059). The median time to recurrence for S-100-positive and S-100-negative patients was 7.6 and 33.8 months, respectively. The median survival time was 59.2 months for S-100-negative patients and 29.6 months for patients positive for S-100.
Conclusions: Serum S-100 shows significant correlations to both time to recurrence and survival and could be useful in the clinical detection of malignant melanoma.
- Schutter EMJ, Visser JJ, van Kamp GJ, et al. The utility of lipid-associated sialic acid (LASA or LSA) as a serum marker for malignancy: a review of the literature.Tumor Biol 1992;13:121–32.
- Katopodis N, Hirshaut Y, Geller NL, Stock CC. Lipid-associated sialic acid test for the detection of human cancer.Cancer Res 1982;42:5270–5.
- Reintgen DS, Cruse CW, Wells KE, Saba HI, Fabri PJ. The evaluation of putative tumor markers for malignant melanoma.Ann Plast Surg 1992;28:55–9.
- Moore BW. A soluble protein characteristic of the nervous system.Biochem Biophys Res Commun 1965;19:739–44. CrossRef
- Nakajima T, Watanabe S, Sato Y, Kameya T, Shimosato Y, Ishihara K. Immunohistochemical demonstration of S-100 protein in malignant melanoma and pigmented nevus, and its diagnostic application.Cancer 1982;50:912–18.
- Stefansson K, Wollmann RL, Moore BW. Distribution of S-100 protein outside the central nervous system.Brain Res 1982;234:309–17. CrossRef
- Fagnart OC, Sindic CJM, Laterre C. Particle counting immunoassay of S-100 protein in serum: possible relevance in tumors and ischemic disorders of the central nervous system.Clin Chem 1988;34(7):1387–91.
- Springall DR, Gu J, Cocchia D, et al. The value of S-100 immunostaining as a diagnostic tool in human malignant melanomas: a comparative study using S-100 and neuron-specific enolase antibodies.Virchows Arch Pathol Anat 1983;400:331–43.
- Gaynor R, Herschman HR, Irie R, Jones P, Morton D, Cochran A. S-100 protein: a marker for human malignant melanomas?Lancet 1981;1:869–71.
- Cho KH, Hashimoto K, Taniguchi Y, Pietruk T, Zarbo RJ, An T. Immunohistochemical study of melanocytic nevus and malignant melanoma with monoclonal antibodies against S-100 subunits.Cancer 1990;66:765–71.
- Kaplan FL, Meier P. Nonparametric estimation from incomplete observations.J Am Stat Assoc 1958;52:457–81.
- Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration.Cancer Chemother Rep 1966;50:163–70.
- Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized trials requiring prolonged observation of each patient II. analysis and examples.Br J Cancer 1997;35:1–39.
- Cox DR. Regression models life tables.J R Stat Soc 1972;34:187–220.
- Bartolucci AA, Fraser MD. Comparative step-upward composite tests for selecting prognostic indicators associated with survival.Biomet J 1977:19;437–48.
- Dorr VJ, Williamson SK, Stephans RL. An evaluation of prostate-specific antigen as a screening test for prostate cancer.Arch Intern Med 1993;153:2529–37. CrossRef
- Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening for prostate cancer.N Engl J Med 1991;324:1156–61.
- Woolfson K. Tumor markers in cancer of the colon and rectum.Dis Colon Rectum 1991;34:506–11. CrossRef
- Martin EW, Cooperman M, Carey LC, Minton JP. Sixty second-look procedures primarily by rise in serial carcinoembryonic antigen.J Surg Res 1980;28:389–94. CrossRef
- Reintgen DS, Cox C, Slingluff CL Jr, Seigler HF. Recurrent malignant melanoma: the identification of prognostic factors to predict survival.Ann Plast Surg 1992;28:45–9.
- Clark HB, Santa Cruz D, Hartman BK, Moore BW. S-100 protein, an immunohistochemical marker for malignant melanoma and other melanocytic lesions [Abstract].Lab Invest 1982;46:13A.
- Cochran AJ, Wen D-R, Herschman HR, Gaynor RB. Detection of S-100 protein as an aid to the identification of melanocytic tumors.Int J Cancer 1982;30:295–7.
- Nakajima T, Watanabe S, Sato Y, Kameya T, Shimosato Y. Immunohistochemical demonstration of S-100 protein in human malignant melanoma and pigmented nevi.Gann 1981;72:335–6.
- Stefansson K, Wollmann R, Jerkovic M. S-100 protein in soft-tissue tumors derived from Schwann cells and melanocytes.Am J Pathol 1982;106:261–8.
- Kahn HJ, Baumal R, Marks A. The value of immunohistochemical studies using antibody to S-100 protein in dermatopathology.Int J Dermatol 1984;23:38–44.
- Kirkwood JM. Present and future applications of the interferons in melanoma [Abstract]. 38th Annual Clinical Conference, Advances in the Biology and Clinical Management of Melanoma. M.D. Anderson Cancer Center, Houston, February 1995.
- Cascinelli N. Evaluation of efficacy of adjuvant rIFN-α 2A in melanoma patients with regional node metastases [Abstract 1296].Proc Am Soc Clin Oncol 1995;14:410.
- Evaluation of new putative tumor markers for melanoma
Annals of Surgical Oncology
Volume 3, Issue 6 , pp 558-563
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Metastatic melanoma
- Tumor marker
- Industry Sectors
- Author Affiliations
- 1. Cutaneous Oncology Program, Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida, USA
- 2. Division of Medical Oncology, Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida, USA
- 3. Dianon Systems, Inc., Stratford, Connecticut, USA